Search
Isaralgagene civaparvovec
go.drugbank.com/drugs/DB16808InvestigationalIt is developed by Sangamo Therapeutics and investigated in Fabry Disease. … Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.
Nisevokitug
go.drugbank.com/drugs/DB17561InvestigationalNisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety … and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Difloxacin
go.drugbank.com/drugs/DB11511ExperimentalVet approvedDifloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration. … However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.
Pratosartan
go.drugbank.com/drugs/DB20100ExperimentalPratosartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Pratosartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Asoprisnil ecamate
go.drugbank.com/drugs/DB20225ExperimentalAsoprisnil ecamate is a small molecule drug. The usage of the INN stem '-nil' in the name indicates that Asoprisnil ecamate is a benzodiazepine receptor antagonist/agonist.
Ripisartan
go.drugbank.com/drugs/DB20229ExperimentalRipisartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Ripisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Furvina
go.drugbank.com/drugs/DB16547ExperimentalFurvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.
Synonyms: 1-(5-Bromofur-2-yl)-2-bromo-2-nitroethenePimicotinib
go.drugbank.com/drugs/DB18972InvestigationalIt was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753] … Pimicotinib is under investigation in clinical trial NCT05804045 (Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)).
Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide